טוען...
Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis
PURPOSE OF REVIEW: Adalimumab is one of the top-selling drugs worldwide. Its imminent patent expiration has seen the emergence of numerous biosimilar agents. In this article, we recap the evidence from bio-originator trials in rheumatoid arthritis (RA) to provide context for a critical review of bio...
שמור ב:
| הוצא לאור ב: | Curr Rheumatol Rep |
|---|---|
| Main Authors: | , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Springer US
2018
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6097048/ https://ncbi.nlm.nih.gov/pubmed/30094742 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11926-018-0769-6 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|